Research Article

Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning

Figure 2

The levels of each serum tumor marker in stage I-III TNBC patients. (a) CEA. (b) CA19-9. (c) CA125. (d) CA242. (e) CA211. (f) CA15-3. A scatter represents a patient, and the cut-off value of each scatter plot is the clinical upper limit, in which higher than the cut-off is indicated by red scatter while the lower is blue. The comparison between different stages was performed using one-way ANOVA and Tukey’s post hoc test or the nonparametric Kruskal-Wallis test as appropriate. , , indicated a significant difference. CEA: carcinoembryonic antigen; CA: cancer antigen; TNBC: triple-negative breast cancer; NS: not significant.
(a)
(b)
(c)
(d)
(e)
(f)